1. Home
  2. CERO vs OBLG Comparison

CERO vs OBLG Comparison

Compare CERO & OBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • OBLG
  • Stock Information
  • Founded
  • CERO 2017
  • OBLG 2000
  • Country
  • CERO United States
  • OBLG United States
  • Employees
  • CERO N/A
  • OBLG N/A
  • Industry
  • CERO
  • OBLG Computer Software: Programming Data Processing
  • Sector
  • CERO
  • OBLG Technology
  • Exchange
  • CERO Nasdaq
  • OBLG Nasdaq
  • Market Cap
  • CERO 5.6M
  • OBLG 5.5M
  • IPO Year
  • CERO N/A
  • OBLG N/A
  • Fundamental
  • Price
  • CERO $5.48
  • OBLG $2.84
  • Analyst Decision
  • CERO Strong Buy
  • OBLG
  • Analyst Count
  • CERO 2
  • OBLG 0
  • Target Price
  • CERO $45.00
  • OBLG N/A
  • AVG Volume (30 Days)
  • CERO 302.9K
  • OBLG 81.1K
  • Earning Date
  • CERO 08-22-2025
  • OBLG 11-06-2025
  • Dividend Yield
  • CERO N/A
  • OBLG N/A
  • EPS Growth
  • CERO N/A
  • OBLG N/A
  • EPS
  • CERO N/A
  • OBLG N/A
  • Revenue
  • CERO N/A
  • OBLG $2,355,000.00
  • Revenue This Year
  • CERO N/A
  • OBLG N/A
  • Revenue Next Year
  • CERO N/A
  • OBLG N/A
  • P/E Ratio
  • CERO N/A
  • OBLG N/A
  • Revenue Growth
  • CERO N/A
  • OBLG N/A
  • 52 Week Low
  • CERO $4.27
  • OBLG $1.91
  • 52 Week High
  • CERO $895.40
  • OBLG $6.70
  • Technical
  • Relative Strength Index (RSI)
  • CERO 31.92
  • OBLG 41.35
  • Support Level
  • CERO $4.27
  • OBLG $2.43
  • Resistance Level
  • CERO $7.60
  • OBLG $3.00
  • Average True Range (ATR)
  • CERO 0.54
  • OBLG 0.24
  • MACD
  • CERO -0.22
  • OBLG 0.02
  • Stochastic Oscillator
  • CERO 27.85
  • OBLG 42.27

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

About OBLG Oblong Inc.

Oblong Inc is a provider of patented multi-stream collaboration products and managed services for network solutions and video collaboration. The company's flagship product Mezzanine is the technology platform that defines computing: simultaneous multi-user, multi-screen, multi-device, and multi-location for dynamic and immersive visual collaboration. Mezzanine transforms routine meetings and workflows into agile, engaging experiences by making data visible and accessible in a collaborative setting. The mezzanine enables multiple, concurrent pieces of content to be shared, manipulated, created, and captured across distance. It serves various industries including aerospace, consulting, executive search, broadcast media, technology, financial services, education, healthcare, and real estate.

Share on Social Networks: